Toronto, Ontario–(Newsfile Corp. – August 26, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses has released the Company’s unaudited condensed consolidated interim 2Q2025 financial statements (“Financial Statements“). Theralase® will be hosting a conference call on Wednesday, September 3rd at 11:00 am ET, which will include a presentation of the financial and operational results for the fiscal quarter ending June 30th, 2025. Questions are welcome. To ensure we have time to review and properly address them during the call, please send them in advance to mperraton@theralase.com. Zoom Meeting Link: https://us02web.zoom.us/j/87203480163Webinar ID: 872 0348 0163 Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) – not required for those attending by Zoom An archived version will be available on the website following the conference call. Financial Summary:For the six-month period ended June 30th: To view an … Read More

Theralase® reported Q1 2025 results showing lower revenue and increased R&D expenses, ongoing Study II enrollment with promising bladder cancer interim data, continued HSV treatment development, and plans for Rutherrin® clinical trials starting early 2026 targeting multiple cancers.

Theralase® will present preclinical data comparing radiation-activated Rutherrin® versus radiation alone at ASTRO 2025, highlighting tumor targeting, immune activation, and survival benefits; clinical trials for various cancers begin early 2026.

Theralase®’s Rutherrin® is 100x more effective than radiation alone in preclinical cancer models, showing tumor targeting, immune activation, and improved survival; Phase I/II clinical trials start early 2026 targeting multiple cancers.

Theralase advances Ruvidar® trials for bladder and other cancers, targeting NDA submissions by 2026, launching multiple Phase I/II studies, seeking US listing, and pursuing international partnerships for commercialization and research collaboration.

Theralase® presented interim Phase II data showing Ruvidar™’s strong safety and efficacy in treating BCG-unresponsive bladder cancer, with durable complete responses, no serious drug-related adverse events, and potential for regulatory approval in 2026.

Theralase® announces Ruvidar™ inhibits Deubiquitinating Enzymes (DUBs), a key factor in cancer and drug resistance. This dual action—blocking DUBs and inducing oxidative stress—makes Ruvidar™ a promising cancer therapy candidate.

Theralase® reported a slight revenue decline in 2024 but reduced net loss, advanced clinical trials for cancer and Parkinson’s treatments, showed promising results in HSV and lymphoma studies, and plans FDA resubmissions.

Theralase® validated University of Manitoba research showing Ruvidar™ is safe and effective against HSV-1. Topical treatment healed lesions in four days, supporting its potential as a herpes therapeutic and clinical candidate.

Theralase® validated Ruvidar™ as safe and effective against HSV-1 in mice, with complete lesion healing in four days, supporting its potential for clinical use and advancement toward human trials.